Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bupropion + fluoxetine is a combination of two antidepressants with different mechanisms of action. Bupropion (Wellbutrin) is a norepinephrine-dopamine reuptake inhibitor (NDRI), while fluoxetine (Prozac) is a selective serotonin reuptake inhibitor (SSRI). This dual-mechanism approach targets different neurotransmitter systems that regulate mood. The combination is sometimes used for treatment-resistant depression or when a patient has had an incomplete response to SSRI therapy alone, potentially providing enhanced antidepressant efficacy and mitigating SSRI-associated sexual dysfunction. However, it requires careful medical supervision due to potential interactions and carries significant risks including increased seizure potential (bupropion lowers the seizure threshold) and possible serotonin syndrome.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupropion + fluoxetine.